safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Articles by safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
Fuzuloparib Monotherapy Improves PFS in Advanced Ovarian Cancer, but Adding Apatinib Offers No Additional Benefit
3
Top 5 Inflammation Articles of 2025
4
Top 5 Myasthenia Gravis Content of 2025
5
